Furthermore, tirzepatide, a novel dual GIP/GLP-1 RA, has shown remarkable efficacy in the management of obesity, in delaying the onset of T2DM among individuals with prediabetes, in reducing HbA1c levels, and improving obesity-related obstructive sleep apnea (OSA) [179,180]. This evidence concerns the gene GIP and obesity disorder.